Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial with APL-106 (Uproleselan Injection) in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

Amy Giles
Increasing Engagement

Joey Cohen
Medication Adherence

Paul Theisen
Patient Acquisition

Bud Bilanich
Success Coach

Daniel Sontupe
Market Access

Stacey Gandler
Brand Nourishment

Liz Kane
Impactful Strategy

David Linetsky
Point-of-Care Marketing

Matt Turner
Patient Affordability

Brenda Snow
Authentic Patient Voice

Frank Burrell
Scientific Storytelling

Pat Purcell
Meeting Engagement

Matthew Durham
Omnidynamic Marketing

Suma Ramadas, PhD
Medical Affairs